Business Wire

DAHUA-THERMAL-SOLUTION

Share
Dahua Thermal Solution Supports Epidemic Prevention and Control

The year 2020 is bound to be a special year with the outbreak of coronavirus disease 2019 (COVID-19) globally. Until today, the highly contagious disease has taken away many lives, especially in China, South Korea, Japan, and some countries in Europe and Middle East.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005479/en/

Dahua Technology, a world-leading video-centric smart IoT solution and service provider, has been an early participant in the epidemic prevention and control in Asia, joining the global efforts in combating the virus to minimize the impact on mankind. Since sending its first batch of thermal cameras to the hardest-hit area Wuhan on January 24th , Dahua thermal solution has been deployed in thousands of sites in China, including transportation hubs, commercial complexes, banks, and other places, and some are on the way to multiple countries in Asia.

Hong Kong, a financial capital in Asia, also suffers from the COVID-19 epidemic situation. Dahua Thermal Solution has been applied in some local business complexes, banks, company parks, and other places. To enable a safe and smooth work resumption recently, quite a few major corporations have been using Dahua Thermal Solution in their headquarters to improve their workplace safety, such as Paul Y. Engineering Group Limited. Dahua Thermal Solution measures the body temperature of their employees, handling thousands of staff flow every day. Compare to the traditional way of body temperature measurement – a forehead thermometer, using Dahua Thermal Solution will significantly improve speed and accuracy, meanwhile help reduce cross-infection via non-contact measurement. To measure the temperature of 5,000 people, it will take about 4.2 hours using a forehead thermometer, as it takes at least 3 seconds to measure a person. However, it takes only 30 minutes if you use Dahua Thermal Solution, which measures 3 person per second. It also features a high accuracy of ±0.3℃ .

“Dahua Thermal Solution helped us detect a couple of suspected cases in just a few hours of operation, which we greatly appreciate,” a Hongkong user commented.

Dahua Thermal Solution has been on the front line since the very beginning, helping with the epidemic prevention and control in airports, railway stations, hospitals, schools, and other sites all over Asia. Featuring high accuracy, high efficiency, strong adaptability and easy deployment, Dahua Thermal Solution can also be applied to all kinds of entrances and exits, kitchens and kindergartens.

Link:

ClickThru

Social Media:

https://www.facebook.com/DahuaHQ/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 10:00:00 CET | Press release

Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne

Energy Transition Solutions Powered by Choice: Trilliant to Share Expertise and Knowledge with Utilities and Smart Cities at Enlit Europe 20256.11.2025 09:00:00 CET | Press release

Product demonstrations and presentations from subject matter experts will highlight key industry insights and the importance of smarter infrastructure to connect systems, empower choice, and unlock performance Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, will be an exhibitor, presenter, and Silver Sponsor at Enlit Europe 2025. With product demonstrations on the exhibition floor and compelling presentations from thought leaders, Trilliant will highlight the importance of energy transition solutions, all powered by choice — that are flexible, scalable and interoperable. Taking place November 18- 20, 2025 in Bilboa, Spain, at the Bilbao Exhibition Centre (BEC), Enlit Europe 2025 is an event designed to connect industries, inspire action, and help Europe evolve into a dependable, decarbonised, and digitalised energy system. “As utilities and smart cities across Europe advance their energy transition

Red Hat Introduces Confirmed Sovereign Support for European Union6.11.2025 09:00:00 CET | Press release

Dedicated, EU-citizen-driven support delivers localized operational control and resilience for digital sovereignty Red Hat, the world's leading provider of enterprise open source solutions, today announced Red Hat Confirmed Sovereign Support for the 27 member states of the European Union to address the critical strategic imperative for digital sovereignty in Europe. This new support offering is purpose-built to deliver dedicated EU-citizen-driven technical support from within the EU for Red Hat software subscriptions, providing a new level of verifiable local control over critical IT operations. More and more European business leaders are looking to digital sovereignty as a way to help drive economic differentiation in a global marketplace, as well as insulate operations from geopolitical dynamics and safeguard EU data, technology and operations. At the same time, these leaders want to further cloud infrastructure resiliency and AI innovation goals through strengthened supply chain tra

IFF Benicarló Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing6.11.2025 09:00:00 CET | Press release

Local site sets a new benchmark for the fragrance industry IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, announced the installation of a nature-based hydrogen production facility at its Scent R&D and fragrance ingredients manufacturing plant in Benicarló, Spain. The site has partnered with Iberdrola, one of the world’s largest producers of renewable energy, to become the first in the fragrance industry to rely on renewable electricity for hydrogenation reactions used in manufacturing key fragrance ingredients. Aligned with the company’s commitment to Do More Good for people and planet, the site’s system can make 100 tons of clean hydrogen annually using renewable energy. It includes a built-in compressor to store hydrogen on-site — reducing the Life Cycle Assessment (LCA) of its products and supporting customers worldwide in achieving their decarbonization goals. This press release features multimedia. View the full release here: https://www

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe6.11.2025 08:00:00 CET | Press release

Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye